Nancy Davidson
Affiliations: | Johns Hopkins University, Baltimore, MD |
Area:
Biochemistry, Molecular BiologyGoogle:
"Nancy Davidson"Mean distance: (not calculated yet)
Children
Sign in to add traineeJulie L. Blum | grad student | 2006 | Johns Hopkins |
Allison M. Pledgie | grad student | 2006 | Johns Hopkins |
Abigail E. Witt | grad student | 2010 | Johns Hopkins |
Talmesha A. Richards | grad student | 2012 | Johns Hopkins |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Yin J, Gu T, Chaudhry N, et al. (2024) Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications. Frontiers in Immunology. 14: 1325615 |
Symonds LK, Davidson NE. (2023) Are we there yet? Optimal duration of endocrine therapy in women with postmenopausal early-stage hormone receptor-positive breast cancer. Journal of the National Cancer Institute |
Garcia-Recio S, Hinoue T, Wheeler GL, et al. (2022) Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nature Cancer |
Francis PA, Fleming GF, Láng I, et al. (2022) Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2201065 |
Davidson NE. (2022) In It for the Long Haul: Long-Term Benefit With Adjuvant Endocrine Therapy for Premenopausal Women With Early-Stage Steroid Receptor-Positive Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2201465 |
Giordano SH, Franzoi MAB, Temin S, et al. (2022) Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2200519 |
Ramakrishna N, Anders CK, Lin NU, et al. (2022) Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2200520 |
Manohar PM, Davidson NE. (2021) Updates in endocrine therapy for metastatic breast cancer. Cancer Biology & Medicine |
Yung RL, Davidson NE. (2021) Optimal adjuvant endocrine therapy for breast cancer. The Lancet. Oncology. 22: 1357-1358 |
Moy B, Rumble RB, Come SE, et al. (2021) Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2101374 |